JPH10502243A - 形質転換哺乳動物のミルクにおける融合タンパク質としてのペプチドの生産 - Google Patents
形質転換哺乳動物のミルクにおける融合タンパク質としてのペプチドの生産Info
- Publication number
- JPH10502243A JPH10502243A JP7526152A JP52615295A JPH10502243A JP H10502243 A JPH10502243 A JP H10502243A JP 7526152 A JP7526152 A JP 7526152A JP 52615295 A JP52615295 A JP 52615295A JP H10502243 A JPH10502243 A JP H10502243A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- milk
- lactalbumin
- protein
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 72
- 235000013336 milk Nutrition 0.000 title claims abstract description 52
- 210000004080 milk Anatomy 0.000 title claims abstract description 52
- 239000008267 milk Substances 0.000 title claims abstract description 51
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 41
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 23
- 241000124008 Mammalia Species 0.000 title claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 235000018102 proteins Nutrition 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 41
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 35
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 35
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 35
- 230000004927 fusion Effects 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 22
- 238000003776 cleavage reaction Methods 0.000 claims abstract description 19
- 230000009261 transgenic effect Effects 0.000 claims abstract description 18
- 230000007017 scission Effects 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims description 23
- 108091026890 Coding region Proteins 0.000 claims description 13
- 108020004414 DNA Proteins 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 9
- 210000004899 c-terminal region Anatomy 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 102000053602 DNA Human genes 0.000 claims description 7
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 7
- 101000946366 Rattus norvegicus Alpha-lactalbumin Proteins 0.000 claims description 6
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 108010013369 Enteropeptidase Proteins 0.000 claims description 5
- 102100029727 Enteropeptidase Human genes 0.000 claims description 5
- 108700019146 Transgenes Proteins 0.000 claims description 5
- 239000002753 trypsin inhibitor Substances 0.000 claims description 5
- 108020004511 Recombinant DNA Proteins 0.000 claims description 4
- 238000003795 desorption Methods 0.000 claims description 4
- 230000003169 placental effect Effects 0.000 claims description 4
- 102000055006 Calcitonin Human genes 0.000 claims description 3
- 108060001064 Calcitonin Proteins 0.000 claims description 3
- 229960004015 calcitonin Drugs 0.000 claims description 3
- 241000289695 Eutheria Species 0.000 claims description 2
- 108010074860 Factor Xa Proteins 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 229960000182 blood factors Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 108010060175 trypsinogen activation peptide Proteins 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 11
- 230000008901 benefit Effects 0.000 abstract description 8
- 238000007112 amidation reaction Methods 0.000 abstract description 5
- 230000004481 post-translational protein modification Effects 0.000 abstract description 5
- 102000014171 Milk Proteins Human genes 0.000 abstract description 4
- 108010011756 Milk Proteins Proteins 0.000 abstract description 4
- 230000009435 amidation Effects 0.000 abstract description 4
- 235000021239 milk protein Nutrition 0.000 abstract description 4
- 210000005075 mammary gland Anatomy 0.000 abstract description 3
- 238000001261 affinity purification Methods 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 241001494479 Pecora Species 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 108010068072 salmon calcitonin Proteins 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000007086 side reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 101710081722 Antitrypsin Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100039087 Peptidyl-alpha-hydroxyglycine alpha-amidating lyase Human genes 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 235000020244 animal milk Nutrition 0.000 description 2
- 230000001475 anti-trypsic effect Effects 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012504 chromatography matrix Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 108010007262 peptidylglycine monooxygenase Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 235000020254 sheep milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010021724 tonin Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LPOMRUVHKIQEQT-KYJUHHDHSA-N (5S)-5-benzyl-1-[4-[(2S)-5,6-dioxo-1-(2-phenylethyl)piperazin-2-yl]butyl]-4-[2-(4-hydroxyphenyl)ethyl]piperazine-2,3-dione Chemical compound C1=CC(O)=CC=C1CCN1C(=O)C(=O)N(CCCC[C@@H]2N(C(=O)C(=O)NC2)CCC=2C=CC=CC=2)C[C@@H]1CC1=CC=CC=C1 LPOMRUVHKIQEQT-KYJUHHDHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UNMYWSMUMWPJLR-UHFFFAOYSA-L Calcium iodide Chemical compound [Ca+2].[I-].[I-] UNMYWSMUMWPJLR-UHFFFAOYSA-L 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000030902 Galactosyltransferase Human genes 0.000 description 1
- 108060003306 Galactosyltransferase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 101000946371 Ovis aries Alpha-lactalbumin Proteins 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 229940046413 calcium iodide Drugs 0.000 description 1
- 229910001640 calcium iodide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- REQPQFUJGGOFQL-UHFFFAOYSA-N dimethylcarbamothioyl n,n-dimethylcarbamodithioate Chemical compound CN(C)C(=S)SC(=S)N(C)C REQPQFUJGGOFQL-UHFFFAOYSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000006251 gamma-carboxylation Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000000121 hypercalcemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 101150085091 lat-2 gene Proteins 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 150000003384 small molecules Chemical group 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 210000003014 totipotent stem cell Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒト以外の胎盤性の形質転換哺乳動物のミルク中でペプチドが融合パートナ ータンパク質に連結した融合タンパク質を発現させ、ミルクから該融合タンパク 質を分離し、さらに該融合タンパク質を切断してペプチドを得ることからなる、 ペプチドの生産方法。 2.該ペプチドは3〜100アミノ酸残基の長さを有する、請求の範囲第1項に 記載の方法。 3.該ペプチドは翻訳後に修飾される、請求の範囲第1項または第2項に記載の 方法。 4.該ペプチドはα−アミド化される、請求の範囲第1項または第2項に記載の 方法。 5.該ペプチドがカルシトニンである、請求の範囲第1項に記載の方法。 6.該融合パートナーはα1−アンチトリプシンである、請求の範囲第1〜5項 のいずれかに記載の方法。 7.該融合パートナーは天然にミルク中に産生されるタンパク質である、請求の 範囲第1〜5項のいずれかに記載の方法。 8.該融合パートナーがα−ラクトアルブミンである、請求の範囲第7項に記載 の方法。 9.該融合タンパク質は疎水性環境からのカルシウム誘導脱離によりミルクから 精製される、請求の範囲第8項に記載の方法。 10.切断が化学的になされる、請求の範囲第1〜9項のいずれかに記載の方法 。 11.臭化シアンを化学的な切断剤として使用する、請求の範囲第10項に記載 の方法。 12.切断が酵素によりなされる、請求の範囲第1〜9項のいずれかに 記載の方法。 13.酵素が血液因子Xaであり、該融合タンパク質は認識配列Ile-Glu-Gly-Ar gを含む、請求の範囲第12項に記載の方法。 14.酵素がエンテロキナーゼであり、該融合タンパク質は認識配列Asp-Asp-As p-Asp-Lysを含む、請求の範囲第12項に記載の方法。 15.切断後に、ペプチドを融合パートナーから分離する、請求の範囲第1〜1 4項のいずれかに記載の方法。 16.ペプチドが疎水性環境からのカルシウム誘導脱離によりα−ラクトアルブ ミンから分離される、請求の範囲第8項及び第14項に記載の方法。 17.ラットのα−ラクトアルブミンのC−末端の拡張を天然に構成するアミノ 酸の少なくとも第1番目を有するC−末端の拡張を有するラット以外のα−ラク トアルブミンからなるタンパク質。 18.ペプチドをコード化する第一のセグメントが融合パートナータンパク質を コード化する第二のセグメントに連結したコーディング配列からなり、該第一及 び第二のセグメント間のDNAは切断可能なリンカー配列をコード化し、該コー ディング配列はコーディング配列をヒト以外の形質転換胎盤性動物のミルク中で 発現できるコントロール配列に操作により連結されたものである、融合タンパク 質をコード化する単離されたまたは組換DNA分子。 19.該分子が請求の範囲第2〜16項のいずれかに記載の特殊な態様によって 特徴付けられるものである、請求の範囲第18項に記載のDNA分子。 20.該コントロール配列がβ−ラクトアルブミンのプロモーターからなる、請 求の範囲第18項または第19項に記載のDNA分子。 21.さらにβ−ラクトアルブミンの3’−非翻訳配列からなる、請求 の範囲第18項、第19項または第20項に記載のDNA分子。 22.ペプチドをコード化する第一のセグメントが融合パートナータンパク質を コード化する第二のセグメントに連結したコーディング配列からなるトランスジ ーン構築物が導入されたゲノムを有し、該第一及び第二のセグメント間のDNA は切断可能なリンカー配列をコード化し、該コーディング配列はコーディング配 列を哺乳動物のミルク中で発現できるコントロール配列に操作により連結された ものである、ヒト以外の形質転換胎盤性哺乳動物。 23.該哺乳動物が請求の範囲第2〜16項のいずれかに記載の特殊な態様によ って特徴付けられるものである、請求の範囲第22項に記載の形質転換哺乳動物 。 24.該コントロール配列がβ−ラクトアルブミンのプロモーターからなる、請 求の範囲第22項または第23項に記載の形質転換哺乳動物。 25.該トランスジーン構築物がさらにβ−ラクトアルブミンの3’−非翻訳配 列からなる、請求の範囲第22項、第23項または第24項に記載の形質転換哺 乳動物。 26.請求の範囲第17項に記載のタンパク質をコード化する組換または単離さ れたDNA分子。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9406974A GB9406974D0 (en) | 1994-04-08 | 1994-04-08 | Transgenic production |
GB9406974.7 | 1994-04-08 | ||
PCT/GB1995/000769 WO1995027782A1 (en) | 1994-04-08 | 1995-04-05 | Peptide production as fusion protein in transgenic mammal milk |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10502243A true JPH10502243A (ja) | 1998-03-03 |
Family
ID=10753224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7526152A Pending JPH10502243A (ja) | 1994-04-08 | 1995-04-05 | 形質転換哺乳動物のミルクにおける融合タンパク質としてのペプチドの生産 |
Country Status (8)
Country | Link |
---|---|
US (2) | US6211427B1 (ja) |
EP (1) | EP0753059A1 (ja) |
JP (1) | JPH10502243A (ja) |
AU (1) | AU707631B2 (ja) |
CA (1) | CA2187173A1 (ja) |
GB (1) | GB9406974D0 (ja) |
NZ (1) | NZ283150A (ja) |
WO (1) | WO1995027782A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002534077A (ja) * | 1999-01-06 | 2002-10-15 | アトランティック バイオファーマシューティカルズ インコーポレイティッド | トランスジェニック動物における分泌型ヒトアルファ−フェト蛋白質の発現 |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9708918D0 (en) * | 1997-05-01 | 1997-06-25 | Ppl Therapeutics Scotland Ltd | Methods |
US6046317A (en) | 1997-12-19 | 2000-04-04 | Hormos Medical Oy, Ltd. | DNA molecule encoding a mutant prepro-neuropeptide Y, a mutant signal peptide, and uses thereof |
US6312898B1 (en) | 1999-04-15 | 2001-11-06 | Hormos Medical Oy, Ltd. | Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene |
EP1194570A1 (en) * | 1999-06-23 | 2002-04-10 | PPL Therapeutics (Scotland) Limited | Fusion proteins incorporating lysozyme |
NZ517774A (en) * | 1999-09-17 | 2005-01-28 | Gtc Biotherapeutics Inc | A method of making a fusion protein such as an immunoglobulin heavy or light chain subunit fused to an enzyme or toxin subunit |
CN1414970A (zh) * | 1999-09-17 | 2003-04-30 | Gtc生物治疗学公司 | 以转基因方式生产的融合蛋白 |
PT1485127E (pt) | 2002-02-25 | 2011-09-07 | Elan Pharm Inc | Administração de agentes para o tratamento de inflamação |
US20060145475A1 (en) * | 2004-12-30 | 2006-07-06 | Itt Manufacturing Enterprises, Inc. | Fluid quick connector with wire retainer |
EP2572734B1 (en) | 2006-10-31 | 2016-04-06 | East Carolina University | Cytokine-based fusion proteins for treatment of immune disorders |
RU2506275C2 (ru) | 2007-11-01 | 2014-02-10 | Астеллас Фарма Инк. | Иммуносупрессорные полипептиды и нуклеиновые кислоты |
JP5524977B2 (ja) | 2008-12-04 | 2014-06-18 | コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー | 高分泌性蛋白質のスクリーニングおよび組換え蛋白質の生産のための融合パートナーとしてのその用途 |
US20120082644A1 (en) | 2009-03-31 | 2012-04-05 | Mannie Mark D | Cytokines and neuroantigens for treatment of immune disorders |
WO2012061074A1 (en) | 2010-10-25 | 2012-05-10 | Elan Pharmaceuticals, Inc. | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS |
US20140314744A1 (en) | 2011-06-06 | 2014-10-23 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗mcam抗體及相關使用方法 |
EP3355910A4 (en) | 2015-09-28 | 2019-08-28 | East Carolina University | ALUMINUM-BASED ADJUVANTS FOR TOLEROGENIC VACCINATION |
EA202191867A1 (ru) * | 2019-01-04 | 2021-10-21 | Репертуар Иммьюн Медисинс, Инк. | Способы получения пептидных библиотек с высоким разнообразием и промотирования фолдинга белка |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4457864A (en) * | 1981-10-23 | 1984-07-03 | University Patents, Inc. | Synthetic analogues of α-melanotropin |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
GB8615942D0 (en) | 1986-06-30 | 1986-08-06 | Animal & Food Research Council | Peptide production |
US5322775A (en) | 1986-06-30 | 1994-06-21 | Pharmaceutical Proteins Ltd. | Peptide production |
GB8826446D0 (en) | 1988-11-11 | 1988-12-14 | Agricultural & Food Res | Peptide production |
ATE114160T1 (de) * | 1989-01-24 | 1994-12-15 | Aphton Corp | Immunogenische zusammensetzungen gegen gastrin- peptide. |
US5620923A (en) | 1989-10-12 | 1997-04-15 | The University Of Utah | Synthesis of peptides as cloned ubiquitin extensions |
GB9028062D0 (en) * | 1990-12-24 | 1991-02-13 | Agricultural & Food Res | Production of transgenic animals |
FR2677652B1 (fr) * | 1991-06-12 | 2005-05-27 | Agronomique Inst Nat Rech | Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee. |
WO1994004672A1 (en) * | 1992-08-26 | 1994-03-03 | Dnx Corp. | Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals |
DE4233152A1 (de) * | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
IL115873A0 (en) | 1995-11-03 | 1996-01-31 | Peri Dev Applic 1985 Ltd | Transgenic protein production |
-
1994
- 1994-04-08 GB GB9406974A patent/GB9406974D0/en active Pending
-
1995
- 1995-04-05 WO PCT/GB1995/000769 patent/WO1995027782A1/en not_active Application Discontinuation
- 1995-04-05 EP EP95913909A patent/EP0753059A1/en not_active Withdrawn
- 1995-04-05 CA CA002187173A patent/CA2187173A1/en not_active Abandoned
- 1995-04-05 NZ NZ283150A patent/NZ283150A/en unknown
- 1995-04-05 AU AU21120/95A patent/AU707631B2/en not_active Ceased
- 1995-04-05 JP JP7526152A patent/JPH10502243A/ja active Pending
-
1996
- 1996-10-08 US US08/727,153 patent/US6211427B1/en not_active Expired - Fee Related
-
1997
- 1997-09-25 US US08/938,595 patent/US6197946B1/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002534077A (ja) * | 1999-01-06 | 2002-10-15 | アトランティック バイオファーマシューティカルズ インコーポレイティッド | トランスジェニック動物における分泌型ヒトアルファ−フェト蛋白質の発現 |
Also Published As
Publication number | Publication date |
---|---|
US6197946B1 (en) | 2001-03-06 |
EP0753059A1 (en) | 1997-01-15 |
CA2187173A1 (en) | 1995-10-19 |
NZ283150A (en) | 1998-05-27 |
AU2112095A (en) | 1995-10-30 |
US6211427B1 (en) | 2001-04-03 |
WO1995027782A1 (en) | 1995-10-19 |
GB9406974D0 (en) | 1994-06-01 |
AU707631B2 (en) | 1999-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10502243A (ja) | 形質転換哺乳動物のミルクにおける融合タンパク質としてのペプチドの生産 | |
JP5568703B2 (ja) | アミド化生成物の調製に有用な酵素を発現させるための細胞株 | |
JPS5863390A (ja) | Dna配列を微生物によつて発現する方法及びその生産物 | |
JPH06505624A (ja) | ペプチド類の精製指向性クローニング | |
GB2241703A (en) | Preparation of IGF-1 and plasmids for use therein | |
JPH01502080A (ja) | 組み換えビタミンk依存性蛋白質のガンマカルボキシル化の増強 | |
EP0123928A2 (en) | Recombinant DNA coding for a polypeptide displaying milk clotting activity | |
JP2637393B2 (ja) | プロインシュリンおよびプレプロインシュリン産生暗号を有するヒト遺伝子 | |
JP2001008697A (ja) | E.コリでの非融合タンパク質の調製方法 | |
Boismenu et al. | Purification and characterization of human and mouse recombinant alpha-fetoproteins expressed inEscherichia coli | |
JPH02501263A (ja) | ヒトの組織因子のクローニングと形質発現 | |
JP2001525664A (ja) | 融合タンパク質を使用するアミド化されたペプチドの製造方法 | |
EP1001980A1 (en) | Recombinant expression of insulin c-peptide | |
JP2000500022A (ja) | タイプixコラーゲン及びそのフラグメント | |
US5082775A (en) | Efficient process for isolating insoluble heterologous protein using non-ionic detergents | |
JPH1175876A (ja) | 新規な微生物トランスグルタミナーゼの製造法 | |
KR0161656B1 (ko) | 글루카곤의 생산방법 | |
EP0422217B1 (en) | Human recombinant placental ribonuclease inhibitor and method of production | |
JPH10313867A (ja) | グルクロン酸転移酵素をコードするdna | |
WO1991002790A1 (en) | Enzymes which participate in c-terminal amidation, and production and use thereof | |
JP2001506489A (ja) | 組換えタンパク質の製造方法 | |
JP2774156B2 (ja) | ヒトプロテインcおよび/または活性化ヒトプロテインc様活性を有する蛋白 | |
JPH044873A (ja) | ペプチドc末端アミド化酵素の製造方法 | |
US6838548B1 (en) | Artiodactyl epimorphine | |
US6888047B1 (en) | Transgenic animals as urinary bioreactors for the production of polypeptide in the urine, recombinant DNA construct for kidney-specific expression, and method of using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040817 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041109 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041220 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050203 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050524 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060426 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060713 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20061017 |